Search - tctmd.com

Displaying 741 - 760 of 1300

Sort: Relevancy | Date

Presentation

Preoperative Statins and Limb Salvage after Lower Extremity Revascularization in the Medicare Population

Presenter: Todd R. Vogel

December 11, 2013

Presentation

Impact of Worsening Renal Dysfunction on the Comparative Efficacy of Bivalirudin and Platelet GPIs

Presenter: E. Perdoncin

December 10, 2013

News Daily News

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

December 10, 2013

Presentation

Effect of Remote Ischemic Preconditioning (IPC) on Platelet Activation and Reactivity Induced by Ablation for A-Fib

Presenter: A. Stazi

December 09, 2013

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Presenter: Eli Lev

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

Presentation

A Randomised Controlled Trial of Platelet Activity Before and After Cessation of Clopidogrel in Patients with Stable Cardiovascular Disease

Presenter: Isobel Ford

November 12, 2013

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

News Daily News

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

Caitlin E. Cox

November 01, 2013

News Daily News

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

Caitlin E. Cox

November 01, 2013

Presentation TCT 2013

Use of Clopidogrel with or without Aspirin in Patients Taking Oral Anticoagulant Therapy and Undergoing Percutaneous Coronary Intervention: an Open-Label, Randomized, Controlled...

Presenter: Freek Verheugt

October 31, 2013

Presentation TCT 2013

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

The Conundrum of Switching DAPT

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Presenter: Kurt Huber

October 31, 2013

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Advertisement

Preoperative Statins and Limb Salvage after Lower Extremity Revascularization in the Medicare Population

Impact of Worsening Renal Dysfunction on the Comparative Efficacy of Bivalirudin and Platelet GPIs

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

Effect of Remote Ischemic Preconditioning (IPC) on Platelet Activation and Reactivity Induced by Ablation for A-Fib

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

A Randomised Controlled Trial of Platelet Activity Before and After Cessation of Clopidogrel in Patients with Stable Cardiovascular Disease

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

Use of Clopidogrel with or without Aspirin in Patients Taking Oral Anticoagulant Therapy and Undergoing Percutaneous Coronary Intervention: an Open-Label, Randomized, Controlled...

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

The Conundrum of Switching DAPT

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content